Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality

Trial Profile

Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Cytarabine/daunorubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Mar 2017 Planned End Date changed from 1 Mar 2021 to 1 May 2021.
    • 06 Dec 2016 Interim analysis results (n=30) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top